Reassessing onco-exceptionalism: equity and resource allocation in immunotherapeutic cancer treatments
Loading...
Date issued
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Reuse License
Abstract
Given that only a small fraction of patients with cancer exhibits specific markers making them eligible for effective targeted therapies, this paper investigates the justification of treating cancer differently in terms of resource allocation when it comes to the application of novel precise therapies—the so-called onco-exceptionalism. Specifically, it assesses whether the reimbursement of expensive drugs is equitable. To do so, we first contextualise healthcare resource allocation concerning immunotherapeutic treatments for cancer, then explore arguments for and against onco-exceptionalism and finally conclude by advocating for a proactive health approach.